SYNGENE384.00

Syngene International Ltd.

· Pharma & Health
₹ CrorePeersSAILIFEDIVISLABWOCKPHARMAGLANDASTERDMPPLPHARMACOHANCELALPATHLABMcap ₹15,471 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Inventory Days (DIO)99.6561.3356.6056.60
Receivable Days (DSO)46.2052.7849.6749.67
Payable Days (DPO)106.75138.84139.20149.24
Cash Conversion Cycle (days)39.10-24.73-32.93-42.97
Working Capital Turnover4.284.096.336.10
Asset Turnover0.570.540.530.53
Cash Conversion (CFO/Net Income)2.042.352.892.89
CFO/EBITDA1.031.121.001.00
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.